Comparative Pharmacology
Head-to-head clinical analysis: PROCHLORPERAZINE versus TRIFLUOPERAZINE HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCHLORPERAZINE versus TRIFLUOPERAZINE HCL.
PROCHLORPERAZINE vs TRIFLUOPERAZINE HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prochlorperazine is a phenothiazine antipsychotic that acts as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) and at high doses in the mesolimbic system. It also has anticholinergic and antiemetic effects.
Trifluoperazine is a typical antipsychotic of the phenothiazine class. It acts primarily as a dopamine D2 receptor antagonist, blocking postsynaptic dopamine receptors in the mesolimbic and mesocortical pathways. It also exhibits moderate anticholinergic, antiadrenergic, and antihistaminergic activity.
5-10 mg IM/IV every 3-4 hours as needed; or 5-10 mg PO 3-4 times daily; or 25 mg PR twice daily. Maximum IM/IV: 40 mg/day; PO: 40 mg/day.
2-10 mg orally twice daily; maximum 40 mg/day. For severe psychosis, 5-20 mg intramuscularly every 4-6 hours, maximum 30 mg/day.
None Documented
None Documented
Clinical Note
moderateProchlorperazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone propionate."
Clinical Note
moderateProchlorperazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Prochlorperazine."
Clinical Note
moderateProchlorperazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate."
Clinical Note
moderateTerminal elimination half-life: 23-25 hours, with prolonged elimination in hepatic impairment.
12-30 hours (terminal elimination half-life); clinical context: requires multiple daily dosing or extended-release formulations for steady-state maintenance.
Renal: 70-80% (as metabolites), Fecal: 20-30% (unchanged and metabolites), Biliary: 10-15% of dose excreted in bile.
Renal (as metabolites, less than 1% unchanged); fecal (biliary) elimination of metabolites accounts for a significant portion; total recovery in urine and feces accounts for >90% of a dose.
Category A/B
Category A/B
Typical Antipsychotic / Antiemetic
Typical Antipsychotic
Prochlorperazine + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine."